Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Curis Inc

CRIS
Current price
11.86 USD -3.13 USD (-20.88%)
Last closed 14.31 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 49 653 024 USD
Yield for 12 month +1 434.28 %
Week
Month
Year
CRIS
21.11.2021 - 28.11.2021

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Address: Building C, Lexington, MA, United States, 02421

Analytics

WallStreet Target Price

28 USD

P/E ratio

Dividend Yield

1.1 %

Current Year

+10 162 000 USD

Last Year

+10 649 000 USD

Current Quarter

+2 833 000 USD

Last Quarter

+2 197 000 USD

Current Year

+9 905 000 USD

Last Year

+10 116 000 USD

Current Quarter

+2 773 000 USD

Last Quarter

+2 123 000 USD

Key Figures CRIS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -46 070 000 USD
Operating Margin TTM -436.57 %
PE Ratio
Return On Assets TTM -27.22 %
PEG Ratio
Return On Equity TTM -110.22 %
Wall Street Target Price 28 USD
Revenue TTM 10 214 000 USD
Book Value 5.03 USD
Revenue Per Share TTM 2.02 USD
Dividend Share
Quarterly Revenue Growth YOY 0.3 %
Dividend Yield 1.1 %
Gross Profit TTM -33 372 000 USD
Earnings Share -9.34 USD
Diluted Eps TTM -9.34 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRIS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRIS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 1.1 %
Last Split Factor 1:5
Payout Ratio
Last Split Date 30.05.2018
Dividend Date 30.05.2018

Stock Valuation CRIS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.0082
Price Sales TTM 5.019
Enterprise Value EBITDA 0.3712
Price Book MRQ 1.3317

Financials CRIS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CRIS

For 52 weeks

3.8 USD 20 USD
50 Day MA 4.43 USD
Shares Short Prior Month 73 388
200 Day MA 1.65 USD
Short Ratio 2.84
Shares Short 83 119
Short Percent 1.42 %